iScience (Jun 2024)

SARS-CoV-2 envelope protein regulates innate immune tolerance

  • Eric S. Geanes,
  • Rebecca McLennan,
  • Stephen H. Pierce,
  • Heather L. Menden,
  • Oishi Paul,
  • Venkatesh Sampath,
  • Todd Bradley

Journal volume & issue
Vol. 27, no. 6
p. 109975

Abstract

Read online

Summary: Severe COVID-19 often leads to secondary infections and sepsis that contribute to long hospital stays and mortality. However, our understanding of the precise immune mechanisms driving severe complications after SARS-CoV-2 infection remains incompletely understood. Here, we provide evidence that the SARS-CoV-2 envelope (E) protein initiates innate immune inflammation, via toll-like receptor 2 signaling, and establishes a sustained state of innate immune tolerance following initial activation. Monocytes in this tolerant state exhibit reduced responsiveness to secondary stimuli, releasing lower levels of cytokines and chemokines. Mice exposed to E protein before secondary lipopolysaccharide challenge show diminished pro-inflammatory cytokine expression in the lung, indicating that E protein drives this tolerant state in vivo. These findings highlight the potential of the SARS-CoV-2 E protein to induce innate immune tolerance, contributing to long-term immune dysfunction that could lead to susceptibility to subsequent infections, and uncovers therapeutic targets aimed at restoring immune function following SARS-CoV-2 infection.

Keywords